Design and Synthesis of a New Series of Highly Potent Raf Kinase-Inhibiting Triarylpyrazole Derivatives Possessing Antiproliferative Activity Against Melanoma Cells

References

• Garbe C , HauschildA, VolkenandtMet al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res.17, 393–399 (2007).
   PubMed Web of Science ®Google Scholar
• Atallah E , FlahertyL. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol.6, 185–193 (2005).
   PubMedGoogle Scholar
• Barth A , WanekLA, MortonDL. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg.181, 193–201 (1995).
   PubMed Web of Science ®Google Scholar
• Anderson CM , BuzaidAC, LeghaSS. Systemic treatments for advanced cutaneous melanoma. Oncol. (Williston Park)9, 1149–1158 (1995).
   PubMedGoogle Scholar
• Gray-Schopfer V , WellbrockC, MaraisR. Melanoma biology and new targeted therapy. Nature445, 851–857 (2007).
   PubMed Web of Science ®Google Scholar
• Garbe C , EigentlerTK. Diagnosis and treatment of melanoma: state of the art in 2006. Melanoma Res.17, 117–127 (2007).
   PubMed Web of Science ®Google Scholar
• Koon HB , AtkinsMB. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev. Anticancer Ther.7, 79–88 (2007).
   PubMed Web of Science ®Google Scholar
• Smith RA , DumasJ, AdnaneL, WilhelmSM. Recent advances in the research and development of RAF kinase inhibitors. Curr. Top. Med. Chem.6, 1071–1089 (2006).
   PubMed Web of Science ®Google Scholar
• Brose MS , VolpeP, FeldmanMet al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62, 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM , CarterC, TangLet al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Mullard A . 2011 FDA drug approvals. Nat. Rev. Drug Discov.11, 91–94 (2012).
   PubMed Web of Science ®Google Scholar
• Luke JJ , HodiFS. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin. Cancer Res.18, 9–14 (2012).
   PubMed Web of Science ®Google Scholar
• Long GV , StroyakovskiyD, GogasHet al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med.371, 1877–88 (2014).
   PubMed Web of Science ®Google Scholar
• El-Gamal MI , SimTB, HongJH, ChoJ-H, YooKH, OhC-H. Synthesis of 1H-pyrazole-1-carboxamide derivatives and their antiproliferative activity against melanoma cell line. Arch. Pharm. Chem. Life Sci.344, 197–204 (2011).
   PubMed Web of Science ®Google Scholar
• El-Gamal MI , OhC-H. Design and synthesis of 3-(3-chloro-4-substituted phenyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide derivatives and their antiproliferative activity against melanoma cell line. Bull. Korean Chem. Soc.32, 821–828 (2011).
   Web of Science ®Google Scholar
• El-Gamal MI , ChoiHS, ChoH-G, HongJH, YooKH, OhC-H. Design, synthesis and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line. Arch. Pharm. Chem. Life Sci.344, 745–754 (2011).
   PubMed Web of Science ®Google Scholar
• Choi W-K , El-GamalMI, ChoiHS, BaekD, OhC-H. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition and molecular docking studies. Eur. J. Med. Chem.46, 5754–5762 (2011).
   PubMed Web of Science ®Google Scholar
• El-Gamal MI , ParkYS, ChiDY, YooKH, OhC-H. New triarylpyrazoles as broad-spectrum anticancer agents: design, synthesis and biological evaluation. Eur. J. Med. Chem.65, 315–322 (2013).
   PubMed Web of Science ®Google Scholar
• El-Gamal MI , ChoiHS, YooKH, BaekD, OhC-H. Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2. Chem. Biol. Drug Des.82, 336–347 (2013).
   PubMed Web of Science ®Google Scholar
• Dean D , TakleA, WilsonD. Preparation of pyridylfurans and pyridylpyrroles as Raf kinase inhibitors. WO 03/022832 A1 (2003).
   Google Scholar
• Reaction Biology Corp . www.reactionbiology.com
   Google Scholar
• Corbeil CR , EnglebienneP, MoitessierN. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J. Chem. Inf. Model.42, 435–449 (2007).
   Google Scholar
• Corbeil CR , EnglebienneP, YannopoulosCGet al. Docking ligands into flexible and solvated macromolecules. 2. Development and application of FITTED 1.5 to the virtual screening of potential HCV polymerase inhibitors. J. Chem. Inf. Model.48, 902–909 (2008).
   PubMed Web of Science ®Google Scholar
• FITTED. The FITTED docking software. http://fitted.ca
   Google Scholar
• RCSB Protein Data Bank . www.rcsb.org/pdb/home/home.do
   Google Scholar
• Wan PT , GarnettMJ, RoeSMet al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell116, 855–867 (2004).
   PubMed Web of Science ®Google Scholar
• Bollag G , HirthP, TsaiJet al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature467, 596–599 (2010).
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G , SongK, YenIet al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature464, 431–435 (2010).
   PubMed Web of Science ®Google Scholar
• Perkin Elmer . www.cambridgesoft.com/
   Google Scholar
• Biovia . http://accelrys.com/
   Google Scholar
• Laskowski RA , SwindellsMB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model.51, 2778–2786 (2011).
   PubMed Web of Science ®Google Scholar
• Weinstock J , GaitanopoulosD, OhHJet al. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2- aminotetralins. J. Med. Chem.29, 1615–1627 (1986).
   PubMed Web of Science ®Google Scholar
• Claudi F , GiorgioniG, Di StefanoA, AbbracchioMP, PaolettiAM, BalduiniW. Synthesis and pharmacological characterization of 2-​(4-​chloro-​3-​hydroxyphenyl)​ethylamine and N,​N-​dialkyl derivatives as dopamine receptor ligands. J. Med. Chem.35, 4408–4414 (1992).
   PubMed Web of Science ®Google Scholar
• Sumitomo H , ImabayashiF, IwataT, KawakamiY. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med.203, 1651–1656 (2006).
   PubMed Web of Science ®Google Scholar
• Yang H , HigginsB, KolinskyK, PackmanK, GoZ, IyerR. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res.70, 5518–5527 (2010).
   PubMed Web of Science ®Google Scholar
• Zheng B , JeongJH, AsaraJMet al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell33, 237–247 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J , YangPL, GrayNS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer9, 28–39 (2009).
   PubMed Web of Science ®Google Scholar
• Cell Bank Australia. Cell Line Information Sheet for MM127 . http://www.phe-culturecollections.org.uk/media/51798/MM127_13440210G_Episode_3_v02.pdf
   Google Scholar
• RCSB. Protein Data Bank . http://www.rcsb.org/pdb/home/home.do
   Google Scholar